Hybrid Collagenase Nanocapsules for Enhanced Nanocarrier Penetration in Tumoral Tissues

Poor penetration of drug delivery nanocarriers within dense extracellular matrices constitutes one of the main liabilities of current nanomedicines. The conjugation of proteolytic enzymes on the nanoparticle surface constitutes an attractive alternative. However, the scarce resistance of these enzym...

ver descrição completa

Detalhes bibliográficos
Autores: Villegas Díaz, María Rocío, Baeza, Alejandro, Vallet Regí, María Dulce Nombre
Formato: artículo
Fecha de publicación:2015
País:España
Recursos:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:español
OAI Identifier:oai:docta.ucm.es:20.500.14352/23171
Acesso em linha:https://hdl.handle.net/20.500.14352/23171
Access Level:acceso abierto
Palavra-chave:546
615.46
Tumoral tissue penetration
Collagenase nanocapsules
Nanomedicine
Mesoporous silica nanodevices and hybrid nanocarriers
Materiales
Química inorgánica (Química)
3312 Tecnología de Materiales
2303 Química Inorgánica
Descrição
Resumo:Poor penetration of drug delivery nanocarriers within dense extracellular matrices constitutes one of the main liabilities of current nanomedicines. The conjugation of proteolytic enzymes on the nanoparticle surface constitutes an attractive alternative. However, the scarce resistance of these enzymes against the action of proteases or other aggressive agents present in the bloodstream strongly limits their application. Herein, a novel nanodevice able to transport proteolytic enzymes coated with an engineered pH-responsive polymeric is presented. This degradable coat protects the housed enzymes against proteolytic attack at the same time that it triggers their release under mild acidic conditions, usually present in many tumoral tissues. These enzyme nanocapsules have been attached on the surface of mesoporous silica nanoparticles, as nanocarrier model, showing a significatively higher penetration of the nanopartides within 3D collagen matrices which housed human osteosarcoma cells (HOS). This strategy can improve the therapeutic efficacy of the current nanomedicines, allowing a more homogeneous and deeper distribution of the therapeutic nanosystems in cancerous tissues.